CYAD.BR
Price:
$0.241
Market Cap:
$9.98M
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's precl...[Read more]
Industry
Biotechnology
IPO Date
2013-07-04
Stock Exchange
EURONEXT
Ticker
CYAD.BR
According to Celyad Oncology SA’s latest financial reports and current stock price. The company's current Enterprise Value is 20.67M. This represents a change of 15.35% compared to the average of 17.92M of the last 4 quarters.
The mean historical Enterprise Value of Celyad Oncology SA over the last ten years is 130.30M. The current 20.67M Enterprise Value has changed 1.49% with respect to the historical average. Over the past ten years (40 quarters), CYAD.BR's Enterprise Value was at its highest in in the December 2015 quarter at 370.86M. The Enterprise Value was at its lowest in in the March 2012 quarter at 0.
Average
130.30M
Median
102.75M
Minimum
-757458.26
Maximum
313.89M
Discovering the peaks and valleys of Celyad Oncology SA Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 160.53%
Maximum Annual Enterprise Value = 313.89M
Minimum Annual Increase = -2835.01%
Minimum Annual Enterprise Value = -757458.26
Year | Enterprise Value | Change |
---|---|---|
2023 | 20.72M | -2835.01% |
2022 | -757458.26 | -102.76% |
2021 | 27.46M | -65.11% |
2020 | 78.70M | -9.01% |
2019 | 86.50M | -40.71% |
2018 | 145.90M | -52.94% |
2017 | 310.02M | 160.53% |
2016 | 119.00M | -62.09% |
2015 | 313.89M | 55.69% |
2014 | 201.62M | 135.03% |
The current Enterprise Value of Celyad Oncology SA (CYAD.BR) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
15.81M
5-year avg
42.52M
10-year avg
130.30M
Celyad Oncology SA’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celyad Oncology SA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Celyad Oncology SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Celyad Oncology SA's Enterprise Value?
What is the highest Enterprise Value for Celyad Oncology SA (CYAD.BR)?
What is the 3-year average Enterprise Value for Celyad Oncology SA (CYAD.BR)?
What is the 5-year average Enterprise Value for Celyad Oncology SA (CYAD.BR)?
How does the current Enterprise Value for Celyad Oncology SA (CYAD.BR) compare to its historical average?